AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients

Disease Markers

Volumn 35, Issue 4, 2013, Pages 207-212

  Hrstka, Roman ^a   Brychtova, Veronika ^a   Fabian, Pavel ^a   Vojtesek, Borivoj ^a   Svoboda, Marek ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTERIOR GRADIENT 2 PROTEIN; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; MESSENGER RNA; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROTEINS; RNA, MESSENGER; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84884949952     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/761537     Document Type: Article

References (16)

1. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002. Ca: A Cancer Journal for Clinicians 2005 55 2 74 108 2-s2.0-14944385553
2. Katzenellenbogen B. S., Frasor J., Therapeutic targeting in the estrogen receptor hormonal pathway. Seminars in Oncology 2004 31 1 28 38 2-s2.0-2142652244
3. Robertson J. F. R., Cannon P. M., Nicholson R. I., Blamey R. W., Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer. International Journal of Biological Markers 1996 11 1 29 35 2-s2.0-0029870691
4. Hrstka R., Nenutil R., Fourtouna A., Maslon M. M., Naughton C., Langdon S., Murray E., Larionov A., Petrakova K., Muller P., Dixon M. J., Hupp T. R., Vojtesek B., The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene 2010 29 34 4838 4847 2-s2.0-77956170869 10.1038/onc.2010.228
5. Innes H. E., Liu D., Barraclough R., Davies M. P. A., O'Neill P. A., Platt-Higgins A., De Silva Rudland S., Sibson D. R., Rudland P. S., Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. British Journal of Cancer 2006 94 7 1057 1065 2-s2.0-33645751864 10.1038/sj.bjc.6603065
6. Thompson D. A., Weigel R. J., hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochemical and Biophysical Research Communications 1998 251 1 111 116 2-s2.0-0032500762 10.1006/bbrc.1998.9440
7. Pohler E., Craig A. L., Cotton J., Lawrie L., Dillon J. F., Ross P., Kernohan N., Hupp T. R., The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Molecular and Cellular Proteomics 2004 3 6 534 547 2-s2.0-3042773498 10.1074/mcp.M300089-MCP200
8. Liu D., Rudland P. S., Sibson D. R., Platt-Higgins A., Barraclough R., Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Research 2005 65 9 3796 3805 2-s2.0-18144426063 10.1158/0008-5472.CAN-04-3823
9. Wang Z., Hao Y., Lowe A. W., The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Research 2008 68 2 492 497 2-s2.0-39049141776 10.1158/0008-5472.CAN-07-2930
10. Hengel S. M., Murray E., Langdon S., Hayward L., O'Donoghue J., Panchaud A., Hupp T., Goodlett D. R., Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance. Journal of Proteome Research 2011 10 10 4567 4578 2-s2.0-80053909031 10.1021/pr2004117
11. Abd El-Rehim D. M., Ball G., Finder S. E., Rakha E., Paish C., Robertson J. F. R., Macmillan D., Blamey R. W., Ellis I. O., High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. International Journal of Cancer 2005 116 3 340 350 2-s2.0-22244449596 10.1002/ijc.21004
12. McCarty K. S. Jr., Miller L. S., Cox E. B., Konrath J., McCarty K. S. Sr., Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Archives of Pathology and Laboratory Medicine 1985 109 8 716 721 2-s2.0-0022358182
13. Hodges L. C., Cook J. D., Lobenhofer E. K., Li L., Bennett L., Bushel P. R., Aldaz C. M., Afshari C. A., Walker C. L., Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Molecular Cancer Research 2003 1 4 300 311 2-s2.0-0037293531
14. Arpino G., Green S. J., Allred D. C., Lew D., Martino S., Osborne C. K., Elledge R. M., HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clinical Cancer Research 2004 10 17 5670 5676 2-s2.0-4444278403 10.1158/1078-0432.CCR-04-0110
15. Dong A., Gupta A., Pai R. K., Tun M., Lowe A. W., The human adenocarcinoma-associated gene, AGR2, induces expression of Amphiregulin through hippo pathway co-activator YAP1 activation. The Journal of Biological Chemistry 2011 286 20 18301 18310 2-s2.0-79955978681 10.1074/jbc.M110.215707
16. Hrstka R., Murray E., Brychtova V., Fabian P., Hupp T. R., Vojtesek B., Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2. Cancer Letters 2013 333 187 193